Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On July 22, 2025, Telix Pharmaceuticals revealed that it “received a subpoena from the U.S. Securities and Exchange Commission . . . seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutics candidates.”
On this news, the price of Telix Pharmaceuticals American Depositary Shares (“ADSs”) fell more than 13% over two trading sessions, according to the complaint.
Then, on August 28, 2025, the complaint further alleges that Telix Pharmaceuticals disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) for the Biologics License Application for its product TLX250-CDx, which identified “deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package.” The FDA additionally “documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission.”
The Telix Pharmaceuticals class action lawsuit alleges that on this news, the price of Telix Pharmaceuticals ADSs fell more than 21% over two trading sessions.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Telix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Telix Pharmaceuticals class action, go to www.faruqilaw.com/TLX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c00df434-1b43-4881-800b-4385df9e694a
